Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendationsKai Rejeski, Ibrahim Yakoub‐Agha, Marion Subklewe et al.|Blood|2023Cited by 330
Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paperIbai Los‐Arcos, Isabel Ruíz-Camps, Gloria Iacoboni et al.|Infection|2020Cited by 143
Obecabtagene autoleucel (obe-cel), a CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, in patients with severe, refractory systemic lupus erythematosus (SLE) in the Phase I CARLYSLE study: Initial safety, preliminary efficacy, pharmacokinetics, and biomarker resultsClaire Roddie, Ruth J. Pepper, Josefina Cortés-Hernández et al.|Blood|2025Cited by 0